Replies to post #158123 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

If any BP offered $5 billion, Linda and -- more importantly -- her limited partners at Toucan, would take it in a heartbeat. That's roughly $2 billion to Toucan, which would be nearly impossible to walk away from if put on the table. In any event, I wouldn't expect anywhere near that kind offer until results are unblinded, which could be quite some time given comments at the ASM.

I'm more interested in what the market cap will be when the publication of the blinded results is released, since that's more immediate.

[antihama]

The deals just keep getting bigger! In today's news

Bristol-Myers Squibb makes history with major multibillion-dollar Nektar drug pact Feb 14, 2018 6:59amby Nick Paul Taylor |
Feb 14, 2018 6:59am

Bristol-Myers is paying $1 billion upfront and buying $850 million in Nektar stock at a 36% premium. (Image: Nektar)
Bristol-Myers Squibb is paying Nektar Therapeutics $1 billion to develop NKTR-214 in combination with Opdivo and Yervoy. All told, Bristol-Myers is committing $3.6 billion to a deal that gives Nektar the lion’s share of NKTR-214 profits and leaves it some freedom to develop the drug in combination with other assets.
Nektar demonstrated the potential of combining immunostimulatory therapy NKTR-214 with Opdivo in November. A phase 1/2 trial of the combination reported objective response rates spanning from 46% to 75% in a range of advanced tumor types, including renal cell carcinoma, melanoma and PD-L1 negative non-small cell lung cancer. The data validated the idea that NKTR-214 boosts the efficacy of checkpoint inhibitors such as Opdivo by expanding NK and T cells and boosting PD-1 expression.
With Bristol-Myers searching for an edge over Merck’s Keytruda and other rival checkpoint inhibitors, the early data have proven compelling enough to encourage it to strike a deal for the asset. Bristol-Myers is paying $1 billion upfront and buying $850 million in Nektar stock at a 36% premium. The Big Pharma will also hand over up to $1.8 billion more in milestones, 80% of which are tied to clinical and regulatory events. The remaining 20% are more distant sales milestones.
The deal is a record-breaker, being the largest biotech licensing fee in history....

https://www.fiercebiotech.com/biotech/bristol-myers-to-pay-1b-upfront-for-stake-nektar-drug?mkt_tok=eyJpIjoiT0RjME16WTJNR1EyWkRGbSIsInQiOiJ0RGE3M1VDd2JuXC9ZalNCTk51dUVyemVuc2M3c1pXQko0YVpGNFpieHlleGJtdlhZWnRXeGNySVpBVmVZd0dJVkxCUElSQjNGYzhhVFYxelNWZ0h1WFJJb3VCMmFYZlwvODh2MnN5VkVneERFeE5SN0ZYWnZTdDdJeEtQdEc5eExqIn0%3D&mrkid=899996

[Milner1]

Smith counts all outstanding stock and warrants but dosent understand nwbo has not received money yet for most of the warrants because they have not been exercised. His additional 100,000,000 needed is way off.

He has no clue when manuscript is coming out, my guess is within 2 weeks.